Tajikistan
Tuberculosis profile
| High MDR-TB burden |
Population  2013 8.2 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.57 (0.43–0.73) 6.9 (5.2–8.9)
Mortality (HIV+TB only) 0.066 (0.044–0.092) 0.8 (0.54–1.1)
Prevalence  (includes HIV+TB) 12 (5.7–20) 142 (70–239)
Incidence  (includes HIV+TB) 8.2 (7.3–9.4) 100 (89–114)
Incidence (HIV+TB only) 0.26 (0.2–0.36) 3.2 (2.5–4.4)
Case detection, all forms (%) 68 (59–76)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 13 (9.8–16) 56 (52–60)
MDR-TB cases among notified pulmonary
TB cases
480 (380–600) 670 (610–720)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 2 205   270
Pulmonary, clinically diagnosed 1 647    
Extrapulmonary 1 454    
       
Total new and relapse 5 576    
Previously treated, excluding relapses 919    
Total cases notified 6 495    
Among 5 306 new cases:
389 (7%) cases aged under 15 years; male:female ratio: 1.3
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 2 205 (100%) 637 (54%) 2 842
Laboratory-confirmed RR-/MDR-TB cases     872
Patients started on MDR-TB treatment     625
TB/HIV 2013 Number (%)
TB patients with known HIV status 5 200 (80)
HIV-positive TB patients 165 (3)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 117 (71)
HIV-positive TB patients on antiretroviral therapy (ART) 162 (98)
HIV-positive people screened for TB 1 944  
HIV-positive people provided with IPT 329  
Treatment success rate (%)
New and relapse cases registered in 2012 83
Previously treated cases, excluding relapse, registered in 2012 75
HIV-positive TB cases, all types, registered in 2012 57
RR-/MDR-TB cases started on second-line treatment in 2011 64
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 1.1
Culture (per 5 million population) 2.4
Drug susceptibility testing (per 5 million population) 0.6
Sites performing Xpert MTB/RIF 11
Is second-line drug susceptibility testing available? Yes, in and outside
country
Financing TB control 2014  
National TB programme budget (US$ millions) 41
% Funded domestically 12%
% Funded internationally 35%
% Unfunded 53%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-04-19 Data: www.who.int/tb/data